(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 January 2006 (05.01.2006)

PCT

(10) International Publication Number
WO 2006/000922 A2

(51) International Patent Classification:
A61K 31/00 (2006.01)

(21) International Application Number:
PCT/IB2005/002768

(22) International Filing Date: 23 June 2005 (23.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/582,182 23 June 2004 (23.06.2004) US

(71) Applicants *(for all designated States except US)*: **IDENIX (CAYMAN) LIMITED**; Walker Secretaries, Walker House, Grand Cayman (KY). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE** [FR/FR]; 3, rue Michel-Ange, F-75794 Paris Cedex 16 (FR). **UNIVERSITA DEGLI STUDI DI CAGLIARI** [IT/IT]; Dip.to Scienze e Tecnologie Biomediche, Sez. Microbiologia e Virologia Generale e Biotecno, logie Microbiche, Cittadella Universitaria SS 554 Km 4,500, I-09042 Monserrato (IT). **UNIVERSTITAT OSNABRUCK LABORATORIUM FUR ORGANIC AND BIORGANIC CHEMIE** [DE/DE]; Barbarastrasse 7, 49069 Osnabruck (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GOSSELIN, Gilles** [FR/FR]; 487, rue Celleneuve St. Hilaire, F-34070 Montpellier (FR). **LA COLLA, Paolo** [IT/IT]; 5 Strada no. 11, Poggio de Pini, I-09012 Capoterra (IT). **SEELA, Frank** [DE/DE]; Universitat Osnabruck Laboratorium fur Organic and, Biorganic Chemie, Barbarastrasse 7, 49069 Osnabruck (DE). **STORER, Richard** [GB/GB]; Sandgate Point, The Leas, Folkestone, Kent CT20 2JE (GB). **DUKHAN, David** [FR/FR]; 42 Impasse Tour Buffel, Res. les Verrieres, F-34070 Montpellier (FR). **LEROY, Frederic** [FR/FR]; Rue de la Font du Loup, F-34725 Jonquieres (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** 5-AZA-7-DEAZAPURINE DERIVATIVES FOR TREATING *FLAVIVIRIDAE*

(57) **Abstract:** This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-flavivirus or anti-pestivirus, biologically active compound has a 5-aza-7-deazapurine moiety. The 5-aza-7-deazapurine moiety may be substituted or unsubstituted, and may comprise a non-nucleoside or nucleoside analogue, or a salt or prodrug thereof. The compound of the present invention may be administered alone or in combination with another anti-hepatitis C, anti-flavivirus and/or anti-pestivirus agent.

WO 2006/000922 A2